Letters
New oral anticoagulants
Safety of new oral anticoagulants in high risk patients
BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1861 (Published 06 March 2014) Cite this as: BMJ 2014;348:g1861
- Stephen Dalgleish, orthopaedic specialty registrar1
- 1NHS Tayside, Ninewells Hospital, Dundee, UK
- sdalgleish{at}nhs.net
Wallace and Davies are rightly worried by the lack of antidotes for new oral anticoagulants.1
Rivaroxaban, a direct factor Xa inhibitor, has been shown to be non-inferior to warfarin for the prevention of stroke and systemic emboli and is associated with comparable levels of bleeding.2 A small preliminary trial found that prothrombin complex concentrate …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.